FDA’s New Classification: Lysosomal Storage Disorder Newborn Screening
Discover the FDA’s strategic decision to classify the lysosomal storage disorder newborn screening test system into class II, complete with special controls. This course offers a detailed examination of what this classification means for safety, effectiveness, and regulatory compliance, and how it can open the door to innovative medical solutions while reducing regulatory burdens.
In this course you will learn the following:
* Understand the classification process and criteria for medical devices.
* Identify the special controls applicable to the lysosomal storage disorder newborn screening test system.
* Recognize the impact of this classification on regulatory burdens and patient access to innovative devices.
NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year. At the end of the one year term, the course will be set to “inactive”.